[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488205":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":31,"locations":40,"responsibleParty":60,"collaborators":64,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":31,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":31,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":31,"overallStatus":43,"whyStopped":31,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","EXPERIMENTAL","This group will receive 100 mg of phenytoin 3 times daily for 6 months.",[13],"Drug: Phenytoin",{"label":15,"type":16,"description":17,"interventionNames":18},"Pentoxifylline group","ACTIVE_COMPARATOR","This group will receive 100 mg of phenytoin 3 times daily plus pentoxifylline 400 mg two times daily for 6 months",[13,19],"Drug: Pentoxifylline 400 MG",{"label":21,"type":16,"description":22,"interventionNames":23},"Celecoxib group","This group will receive 100 mg of phenytoin 3 times daily plus celecoxib 200 mg once daily for 6 months",[13,24],"Drug: Celecoxib 200mg",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Phenytoin","Phenytoin remains a highly effective anti-epileptic drug, especially in generalized seizure management. Unfortunately, phenytoin efficacy on epileptic seizure is apparently reduced with its chronic use",[21,9,15],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Pentoxifylline 400 MG","Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy",[15],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Celecoxib 200mg","Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis",[21],[41],{"facility":42,"status":43,"city":44,"state":31,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Mansoura University","RECRUITING","Al Mansurah","35516","Egypt","EG",{"type":49,"coordinates":50},"Point",[51,52],31.38069,31.03637,{"lat":52,"lon":51},[55],{"name":56,"role":57,"phone":58,"phoneExt":31,"email":59},"Maha Younis, PhD","CONTACT","0201069491494","myounis@horus.edu.eg",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"SPONSOR_INVESTIGATOR","Mostafa Bahaa","Teaching Assistant",[65,66],{"name":5,"class":6},{"name":67,"class":68},"Principal Investigator Maha Ahmed Younis, PhD Pharmacy Practice Department- Horus University","UNKNOWN","100488205","phase-2-clinical-study-evaluating-safety-of-pentoxifylline-and-celecoxib-in-patients-with-grand-mal-epilepsy-treated-by-phenytoin-monotherapy-100488205",false,"NCT05637086","Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy","Clinical Study Evaluating and Comparing the Safety and the Possible Efficacy of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy","Inclusion Criteria:\n\n\\- Patients aged ≥ 18 years old. Patients with grand mal epilepsy on phenytoin monotherapy. Women with a negative pregnancy test and women on effective contraception\n\nExclusion Criteria:\n\n\\- Patients with significant liver and kidney function abnormalities. Alcohol and\u002For drug abusers. Patients with known allergies to the study medications Patients with known allergy to sulfonamides (cross hypersensitivity with celecoxib).\n\nPregnant women and women with a planned pregnancy. Subjects on medication are known to have possible positive effects on epilepsy. Patients who are currently using other antiepileptic drugs. Patients with CVD and a history of coronary artery bypass graft (CABG) surgery. Patients on aspirin or fluconazole therapy Patients with a recent retinal or cerebral hemorrhage","ALL","18 Years","75 Years",{"count":80,"type":81},90,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","Epilepsy is a chronic neurological disorder affecting millions of people all over the world. Epileptic seizures are caused by abnormal synchronized electrical neuronal discharges that could be either focal or widespread. Pathogenesis of epilepsy involves multiple processes including genetics, oxidative stress, ion channels, neuroinflammation, and cellular damage through autophagy and apoptosis.\n\nNeuroinflammation is considered one of the most important factors contributing critically to epileptogenesis.",[87],"Epilepsy","2024-07-16",{"date":90,"type":91},"2024-07-18","ACTUAL",{"date":93,"type":91},"2022-12-20",{"date":95,"type":81},"2027-11-20",{"name":62,"class":6},1]